Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$-0.47
EPS est.
$0.02
EPS surprise
-2450.00%
1-day move
+1.06%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Mirum Pharmaceutical faced significant challenges in the fourth quarter, particularly with EPS performance. Despite the miss, the stock saw a modest increase of 1.06%, likely driven by investor optimism about the company's future potential and ongoing efforts to improve its product pipeline. The lack of revenue data and guidance may leave some investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | -2450.00% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the current financial performance but highlighted their commitment to enhancing the company's offerings. They did not provide any forward guidance, leaving investors uncertain about future expectations.
Management acknowledged challenges in meeting expectations.
They emphasized ongoing efforts to improve product pipeline.
No specific guidance was provided for future quarters.